Cargando…

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China

Objective. This study was designed to compare the effects of metformin and repaglinide on the fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) in newly diagnosed type 2 diabetes in China. Methods. A total of 107 newly diagnosed type 2 diabetic patients (46 women and 61 men) participated...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, J., Liu, L. Y., Wu, P. H., Liao, Y., Tao, T., Liu, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960773/
https://www.ncbi.nlm.nih.gov/pubmed/24772445
http://dx.doi.org/10.1155/2014/294017
_version_ 1782308195123855360
author Ma, J.
Liu, L. Y.
Wu, P. H.
Liao, Y.
Tao, T.
Liu, W.
author_facet Ma, J.
Liu, L. Y.
Wu, P. H.
Liao, Y.
Tao, T.
Liu, W.
author_sort Ma, J.
collection PubMed
description Objective. This study was designed to compare the effects of metformin and repaglinide on the fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) in newly diagnosed type 2 diabetes in China. Methods. A total of 107 newly diagnosed type 2 diabetic patients (46 women and 61 men) participated in the study. All patients received 3-month treatment of metformin or repaglinide. Fasting blood glucose and HbA1c were determined at baseline and at the end of the 3-month of treatment. Results. FPG and HbA1c decreased in both metformin and repaglinide groups after 3 months treatment (P < 0.01). The reduction of HbA1c was significantly greater in the repaglinide group (P < 0.01). Metformin decreases fasting insulin concentration and HOMA-IR (P < 0.01), and repaglinide improves HOMA-β  (P < 0.01). Triglycerides (TG) were reduced in both groups (P < 0.01 in metformin group; P < 0.05 in repaglinide group), but total cholesterol (TC) and low-density lipoprotein (LDL) were decreased only after metformin treatment (P < 0.05). Conclusions. Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China. Repaglinide had no effect on insulin sensitivity, but it improved β-cell function.
format Online
Article
Text
id pubmed-3960773
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39607732014-04-27 Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China Ma, J. Liu, L. Y. Wu, P. H. Liao, Y. Tao, T. Liu, W. J Diabetes Res Clinical Study Objective. This study was designed to compare the effects of metformin and repaglinide on the fasting plasma glucose (FPG) and glycated haemoglobin (HbA1c) in newly diagnosed type 2 diabetes in China. Methods. A total of 107 newly diagnosed type 2 diabetic patients (46 women and 61 men) participated in the study. All patients received 3-month treatment of metformin or repaglinide. Fasting blood glucose and HbA1c were determined at baseline and at the end of the 3-month of treatment. Results. FPG and HbA1c decreased in both metformin and repaglinide groups after 3 months treatment (P < 0.01). The reduction of HbA1c was significantly greater in the repaglinide group (P < 0.01). Metformin decreases fasting insulin concentration and HOMA-IR (P < 0.01), and repaglinide improves HOMA-β  (P < 0.01). Triglycerides (TG) were reduced in both groups (P < 0.01 in metformin group; P < 0.05 in repaglinide group), but total cholesterol (TC) and low-density lipoprotein (LDL) were decreased only after metformin treatment (P < 0.05). Conclusions. Both repaglinide and metformin were effective in glycaemic control in new onset patients with type 2 diabetes in China. Repaglinide had no effect on insulin sensitivity, but it improved β-cell function. Hindawi Publishing Corporation 2014 2014-03-04 /pmc/articles/PMC3960773/ /pubmed/24772445 http://dx.doi.org/10.1155/2014/294017 Text en Copyright © 2014 J. Ma et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Ma, J.
Liu, L. Y.
Wu, P. H.
Liao, Y.
Tao, T.
Liu, W.
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
title Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
title_full Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
title_fullStr Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
title_full_unstemmed Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
title_short Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
title_sort comparison of metformin and repaglinide monotherapy in the treatment of new onset type 2 diabetes mellitus in china
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960773/
https://www.ncbi.nlm.nih.gov/pubmed/24772445
http://dx.doi.org/10.1155/2014/294017
work_keys_str_mv AT maj comparisonofmetforminandrepaglinidemonotherapyinthetreatmentofnewonsettype2diabetesmellitusinchina
AT liuly comparisonofmetforminandrepaglinidemonotherapyinthetreatmentofnewonsettype2diabetesmellitusinchina
AT wuph comparisonofmetforminandrepaglinidemonotherapyinthetreatmentofnewonsettype2diabetesmellitusinchina
AT liaoy comparisonofmetforminandrepaglinidemonotherapyinthetreatmentofnewonsettype2diabetesmellitusinchina
AT taot comparisonofmetforminandrepaglinidemonotherapyinthetreatmentofnewonsettype2diabetesmellitusinchina
AT liuw comparisonofmetforminandrepaglinidemonotherapyinthetreatmentofnewonsettype2diabetesmellitusinchina